Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-21-000708
Filing Date
2021-06-22
Accepted
2021-06-21 20:17:56
Documents
2
Group Members
ORBIMED CAPITAL GP VIII LLCORBIMED CAPITAL LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss333892_sc13d.htm SC 13D 137832
2 JOINT FILING AGREEMENT ss333892_ex9901.htm EX-99.1 7501
  Complete submission text file 0000947871-21-000708.txt   146917
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92596 | Film No.: 211032681
SIC: 2834 Pharmaceutical Preparations